Literature DB >> 2081167

[Tetanus in adults: mortality. Study in 130 cases].

R Ramírez Miñana1, T Sicilia Lafont, J L Aguilera, J M César, B Domínguez, J Soto.   

Abstract

Out of the 557 cases of tetanus in adult patients seen in our institution over 61 years, we have selected for analysis the 130 patients who where admitted to our service since its creation in 1968. We have found a trend toward older patient age in recent years. The age distribution showed a bimodal curve which was maintained in the different periods and was due, in the last one to the population of parenteral drug abusers. In the last 20 years there has been an increase in severe forms (p less than 0.001). The mortality was statistically associated with clinical severity (p less than 0.001) and with the surgical portal of entry (p less than 0.05). The development of intensive care reduced the mortality rate from 58.3% in the period before ICU to 24.6% in the 130 patients cared for since the service was created (p less than 0.001). In the last 10 years, the mortality rate of 41 patients was 9.7%. The most common cause of death was cardiac arrest (68.7%). Superinfection was the second cause (25%). The use of beta-blockers in patients with severe tetanus, with significant autonomic abnormalities, reduced the mortality from 72.7% to 14.8% (p less than 0.001). The mortality of superinfection has been maintained, without statistically significant changes.

Entities:  

Mesh:

Year:  1990        PMID: 2081167

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  1 in total

1.  Patients with severe accidental tetanus admitted to an intensive care unit in Northeastern Brazil: clinical-epidemiological profile and risk factors for mortality.

Authors:  Marcus Vinícius Dantas da Nóbrega; Ricardo Coelho Reis; Isabel Cristina Veras Aguiar; Timóteo Vasconcelos Queiroz; Ana Claudia Feitosa Lima; Eanes Delgado Barros Pereira; Raquel Feijó de Araújo Ferreira
Journal:  Braz J Infect Dis       Date:  2016-07-29       Impact factor: 3.257

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.